Intellia Therapeutics (NTLA) Upgraded by TheStreet to “C-“

TheStreet upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a d rating to a c- rating in a research note issued to investors on Monday.

A number of other brokerages also recently weighed in on NTLA. BidaskClub raised Intellia Therapeutics from a buy rating to a strong-buy rating in a research report on Tuesday, March 13th. JMP Securities assumed coverage on Intellia Therapeutics in a research report on Thursday, March 8th. They set an outperform rating on the stock. Barclays boosted their price target on Intellia Therapeutics from $33.00 to $46.00 and gave the stock an overweight rating in a research report on Wednesday, March 7th. Wedbush reissued an outperform rating and set a $36.00 price target on shares of Intellia Therapeutics in a research report on Thursday, March 15th. Finally, Leerink Swann reissued an outperform rating on shares of Intellia Therapeutics in a research report on Wednesday, March 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company’s stock. Intellia Therapeutics has a consensus rating of Buy and a consensus target price of $34.83.

How to Become a New Pot Stock Millionaire

Shares of Intellia Therapeutics stock opened at $23.05 on Monday. The stock has a market capitalization of $1,007.55, a PE ratio of -12.39 and a beta of 2.42. Intellia Therapeutics has a 12-month low of $11.15 and a 12-month high of $35.99.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Wednesday, March 14th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.16). The company had revenue of $6.70 million during the quarter, compared to analyst estimates of $8.84 million. Intellia Therapeutics had a negative net margin of 258.62% and a negative return on equity of 31.27%. Intellia Therapeutics’s revenue was up 19.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.31) EPS. equities research analysts predict that Intellia Therapeutics will post -2.27 earnings per share for the current fiscal year.

In other news, Director Jean Francois Formela sold 39,245 shares of the company’s stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $23.87, for a total value of $936,778.15. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $26.78, for a total value of $14,746,273.10. The disclosure for this sale can be found here. 12.80% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the company. TIAA CREF Investment Management LLC grew its position in shares of Intellia Therapeutics by 5.4% in the fourth quarter. TIAA CREF Investment Management LLC now owns 40,415 shares of the company’s stock valued at $777,000 after purchasing an additional 2,076 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Intellia Therapeutics by 12.5% in the fourth quarter. California State Teachers Retirement System now owns 26,272 shares of the company’s stock valued at $505,000 after purchasing an additional 2,929 shares during the last quarter. Deutsche Bank AG grew its position in shares of Intellia Therapeutics by 8.5% in the fourth quarter. Deutsche Bank AG now owns 41,744 shares of the company’s stock valued at $800,000 after purchasing an additional 3,279 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Intellia Therapeutics by 61.3% in the third quarter. SG Americas Securities LLC now owns 10,169 shares of the company’s stock valued at $253,000 after purchasing an additional 3,863 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in shares of Intellia Therapeutics by 22.4% in the fourth quarter. Teachers Advisors LLC now owns 31,950 shares of the company’s stock valued at $614,000 after purchasing an additional 5,856 shares during the last quarter. 67.02% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Intellia Therapeutics (NTLA) Upgraded by TheStreet to “C-“” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.chaffeybreeze.com/2018/03/23/intellia-therapeutics-ntla-upgraded-by-thestreet-to-c.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply